A Phase 3 interventional study of Frexalimab and Teriflunomide in Multiple Sclerosis, sponsored by Sanofi. Active, not recruiting at 382 sites in 41 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Multiple Sclerosis by Sanofi — 3 open to participants now, 6 under way, 4 of them phase 3. Multiple Sclerosis · Sanofi.
Among the 44 studies in Multiple Sclerosis by Sanofi, this one is the 2nd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2023, is one of 18 in phase 3, and was the 40th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 44 studies in Multiple Sclerosis by Sanofi are open now, in 8 countries. Recruiting first, the newest first:
Sanofi · Sites in United Arab Emirates
Ages 18+
Sanofi · Sites in United States, Belgium, Brazil and 4 more countries
Ages 18–60
Sanofi
Ages 18–60
By country, each count listing its studies:
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,655 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 166 across the 41 interventional studies, 220 across the 3 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Multiple Sclerosis by Sanofi that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Multiple Sclerosis by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant must have at least 1 of the following prior to screening:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Frexalimab infusion and placebo tablet.
Drug: Frexalimab · Drug: Placebo tablet · Drug: MRI contrast-enhancing agents · Drug: Cholestyramine · Drug: Activated charcoal
Participants will receive teriflunomide tablet and placebo infusion.
Drug: Teriflunomide · Drug: Placebo infusion · Drug: MRI contrast-enhancing agents · Drug: Cholestyramine · Drug: Activated charcoal
SAR441344 Solution for IV infusion
Aubagio oral tablet
Solution for IV infusion
Oral tablet
IV, as per respective label
oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapses
ARR during the study period assessed by protocol-defined adjudicated relapses. This endpoint will be analyzed in the ITT population of each study using a negative binomial model with the total number of adjudicated relapses per participant occurring during the observation period as the response variable and with terms for treatment group, Gd-enhancing T1 lesions at baseline (presence, absence), EDSS strata (\<4, ≥4), and geographical region (US, non-US).
Time frame: Until Week 156
Time to onset of composite confirmed disability worsening (cCDW)
confirmed over 6 months as assessed by the composite of: * increase from the baseline expanded disability status scale (EDSS) score of ≥1.5 points when the baseline is 0, or ≥1.0 point when the baseline is 0.5 to 5.0, or ≥0.5 point when the baseline is ≥5.5, OR * increase of ≥20% from the baseline time in the 9-hole peg test (9HPT), OR * increase of ≥20% from the baseline time in the Timed 25-foot walk (T25FW) test
Time frame: Until Week 156
Time to onset of cCDW, confirmed over 3 months
Time frame: Until Week 156
Time to onset of individual components of the composite, confirmed over 3-months or 6-months
Time frame: Until Week 156
Time to onset of confirmed disability improvement (CDI)
defined as decrease from baseline EDSS score of ≥1.0 or ≥ 0.5 points when the baseline is ≥2 to ≤5.5 or \>5.5 points, respectively, confirmed over 6 months. No improvement possible for 0 to 1.5 points
Time frame: Until Week 156
Progression independent of relapse activity defined as the time to onset of 6-month cCDW
defined by either no prior relapse or an onset more than 90 days after the start date of the last adjudicated relapse
Time frame: Until Week 156
Total number of new and/or enlarging T2 hyperintense lesions as detected by MRI
defined as the sum of the individual number of new and/or enlarging T2 lesions at all scheduled visits starting after baseline up to and including the EOS visit
Time frame: Until Week 156
Total number of new Gd-enhancing T1hyperintense lesions per scan as detected by MRI
defined as the sum of the individual number of new Gd enhancing T1-hyperintense lesions at all scheduled visits starting after baseline up to and including the EOS visit divided by the number of scans
Time frame: Until Week 156
Percent change in brain volume loss as detected by brain MRI scans at the EOS compared to Month 6
Time frame: From Week 24 to Week 156
Change in cognitive function at the EOS compared to baseline as assessed by the symbol digit modalities test (SDMT)
Time frame: From baseline to Week 156
Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time
Time frame: From baseline to Week 156
Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue MS-8 over time
Time frame: Until Week 156
Number of participants with adverse events, SAEs, AEs leading to permanent study intervention discontinuation, AESIs and safety scales during the study period
Time frame: Until Week 168
Number of participants with potentially clinically significant abnormality (PCSAs) in laboratory tests, ECG and vital signs during the study period
12-lead ECG (electrocardiogram) will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.
Time frame: Until Week 168
Number of participants with antidrug (ADAs) over time
Time frame: Until Week 156
Change from baseline in plasma neurofilament light chain (NfL) levels over time
Time frame: Until Week 144
Frexalimab plasma concentration over time
Time frame: Until Week 144
Showing the first 100 of 382 sites across 41 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Dec 2023 (actual). Primary completion is estimated for May 2027, 40 months after the start.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 40 months is close to that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frexalimab